SymBio Pharmaceuticals Limited

4582.T
Drug Manufacturers - Specialty & Generic
2026/10/02 18:47 Updated
Market Cap: $28.4M (¥4.5B)
Stock Price: $0.35 (¥56)
Exchange Rate: 1 USD = ¥157.98

Notice Regarding the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)

Published the monthly exercise status for September 2026 of the 70th and 71st stock acquisition rights. Number of shares granted: 4,300,000 shares; number of rights actually exercised in September: 43,000; ratio to total issued: 9.0%; unexercised rights: 437,000; exercise restriction: 5.4% (based on listing rules).

Importance:
Page Updated: October 2, 2026
IR Disclosure Date: October 1, 2026

Key Figures

  • Number of shares granted: 4,300,000 shares
  • Number of stock acquisition rights exercised: 43,000 items
  • Number of unexercised stock acquisition rights: 437,000 items

AI要約

Overview of Exercise Status of Stock Acquisition Rights

Impact and Background

For details on the operation of stock acquisition rights with an exercise price adjustment clause, refer to the notice related to the unsecured bond facility agreement. The monthly exercise ratio, as an indicator of potential dilution risk to the market, has generally remained low. Meanwhile, the rights allocated to the EVO FUND have special restrictions, and future exercise trends may vary depending on contractual conditions and timing of instructions.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

SymBio Pharmaceuticals Limited

Company overview · Stock price · Financial data · All IR

View company page →